See more : Greentech Technology International Limited (0195.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Alector, Inc. (ALEC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alector, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Madhav Infra Projects Limited (MADHAVIPL.BO) Income Statement Analysis – Financial Results
- Getchell Gold Corp. (GGLDF) Income Statement Analysis – Financial Results
- Mirai Works Inc. (6563.T) Income Statement Analysis – Financial Results
- Payoneer Global Inc. (PAYO) Income Statement Analysis – Financial Results
- Invincible Investment Corporation (IVINF) Income Statement Analysis – Financial Results
Alector, Inc. (ALEC)
About Alector, Inc.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 97.06M | 133.62M | 207.09M | 21.10M | 21.22M | 27.68M | 3.74M | 416.00K |
| Cost of Revenue | 192.12M | 8.47M | 189.41M | 156.87M | 100.53M | 73.03M | 29.91M | 13.67M |
| Gross Profit | -95.05M | 125.15M | 17.68M | -135.77M | -79.31M | -45.35M | -26.18M | -13.26M |
| Gross Profit Ratio | -97.93% | 93.66% | 8.54% | -643.53% | -373.76% | -163.87% | -700.83% | -3,187.02% |
| Research & Development | 192.12M | 210.42M | 189.41M | 156.87M | 100.53M | 73.03M | 29.91M | 13.67M |
| General & Administrative | 56.69M | 61.03M | 55.04M | 59.40M | 35.10M | 11.93M | 6.50M | 1.87M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 56.69M | 61.03M | 55.04M | 59.40M | 35.10M | 11.93M | 6.50M | 1.87M |
| Other Expenses | 0.00 | 7.78M | 1.03M | 4.95M | 9.02M | 5.04M | 199.00K | 22.00K |
| Operating Expenses | 248.80M | 271.45M | 244.45M | 216.27M | 135.62M | 84.97M | 36.41M | 15.55M |
| Cost & Expenses | 248.80M | 271.45M | 244.45M | 216.27M | 135.62M | 84.97M | 36.41M | 15.55M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 8.85M | 8.47M | 8.31M | 7.27M | 5.57M | 1.02M | 680.00K | 201.00K |
| EBITDA | -142.89M | -129.36M | -29.05M | -187.91M | -109.47M | -56.27M | -32.00M | -14.93M |
| EBITDA Ratio | -147.22% | -103.16% | -18.04% | -925.08% | -539.16% | -206.99% | -856.73% | -3,589.18% |
| Operating Income | -151.74M | -137.83M | -37.36M | -195.17M | -114.40M | -57.29M | -32.68M | -15.13M |
| Operating Income Ratio | -156.33% | -103.16% | -18.04% | -925.08% | -539.16% | -206.99% | -874.94% | -3,637.50% |
| Total Other Income/Expenses | 26.56M | 7.78M | 1.03M | 4.95M | 9.02M | 5.04M | 199.00K | 22.00K |
| Income Before Tax | -125.18M | -130.06M | -36.33M | -190.23M | -105.39M | -52.25M | -32.48M | -15.11M |
| Income Before Tax Ratio | -128.97% | -97.33% | -17.54% | -901.64% | -496.65% | -188.78% | -869.61% | -3,632.21% |
| Income Tax Expense | 5.21M | 3.25M | -8.32M | -7.27M | -5.57M | 5.04M | 0.00 | 0.00 |
| Net Income | -130.39M | -133.31M | -28.01M | -182.96M | -99.81M | -52.25M | -32.48M | -15.11M |
| Net Income Ratio | -134.34% | -99.77% | -13.53% | -867.21% | -470.39% | -188.78% | -869.61% | -3,632.21% |
| EPS | -1.56 | -1.62 | -0.35 | -2.35 | -1.62 | -0.76 | -0.63 | -0.29 |
| EPS Diluted | -1.56 | -1.62 | -0.35 | -2.35 | -1.62 | -0.76 | -0.63 | -0.29 |
| Weighted Avg Shares Out | 83.73M | 82.47M | 80.42M | 77.76M | 61.73M | 68.37M | 51.22M | 51.22M |
| Weighted Avg Shares Out (Dil) | 83.73M | 82.47M | 80.42M | 77.76M | 61.73M | 68.37M | 51.22M | 51.22M |
Alector: Q4 2024 Data Release Could Provide Major Shift For Valuation
Alector Announces Pricing of Public Offering of Common Stock
Alector Announces Proposed Public Offering of Common Stock
Wall Street Analysts Think Alector (ALEC) Could Surge 142.53%: Read This Before Placing a Bet
These biotechs targeting multiple neurodegenerative diseases
Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs
Alector (ALEC) Loses -38.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Alector to Participate in the Stifel Healthcare Conference
Alector Reports Third Quarter 2023 Financial Results and Provides Business Update
Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
Source: https://incomestatements.info
Category: Stock Reports